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INTRODUCTION:
Mounting evidence suggests that dysregulation of fatty acid synthase (FAS), the rate limiting multienzyme in the de novo formation of free fatty acids, is an early and important step in carcinogenesis and transformation to aggressive prostate cancer. Excess production of free fatty acids by FAS occurs through enhanced synthesis of malonyl-coA from acetyl-CoA and leads to increased cellular triglyceride formation and deposition. Thus we hypothesize that increased intraprostatic lipid concentration as measured by 1H Magnetic Resonance Spectroscopy (MRSI) will identify tissues with higher FAS activity, which in turn will be those that exhibit more aggressive disease. In more aggressive cancer tissues, we expect to find metabolic signatures of enhanced fatty acid oxidation. In showing an association between FAS protein overexpression by histology, in-vivo intraprostatic fat as measured by 1H MRSI, metabolic signatures of lipid oxidation and metabolism, and prostate cancer aggressiveness, our objective is to provide support for the novel application of this imaging modality for use in the clinical setting to determine the proper management of newly diagnosed prostate cancer. Specifically, among men diagnosed with low grade (proposed as more indolent) and high grade (proposed as more aggressive) prostate cancer (as determined by the 2011 National Comprehensive Cancer Network (NCCN) guidelines [6]) we propose to 1) determine the correlation between the amount of intraprostatic lipid using 1H magnetic resonance spectroscopic imaging (MRSI) with an endorectal coil obtained prior to prostatectomy with FAS protein expression measured in benign and cancer tissue from prostatectomy samples; 2) identify the association between FAS protein expression in prostatectomy samples, intraprostatic lipid as measured by 1H MRSI, and prostate tumor aggressiveness; and 3) quantify the association between key metabolic intermediates involved in lipid metabolism, mitochondrial function, inflammation, and apoptosis in prostatectomy samples and FAS protein expression, intraprostatic lipid and tumor aggressiveness.
BODY:
Department of Defense funding to allow initiation of this project was set up and received locally at the end of January/ beginning of February, 2013. From that point forward we have made progress in meeting the following items from our statement of work as described below (full SOW attached). (Figure 1 ).
Compensate men for their participation in study (Shannon & Purnell)
Within a month of a man participating on our trial, they have either been compensated for a successful MRI and/or travel reimbursement.
KEY RESEARCH ACCOMPLISHMENTS:
Bulleted list of key research accomplishments emanating from this research.
• Portland VA Medical Center (PVAMC) IRB approval as of 9/9/2012.
• Standing monthly investigational team meeting initiated 11/8/2012.
• Added Medical Monitor, Arthur Hung, MD to project 11/14/2012.
• Oregon Health & Science University (OHSU) IRB approval as of 12/28/2012.
• Initiation of enrollment; first participant consented to study 2/22/2013.
• Continuing review PVAMC IRB approval 3/12/2013.
• Modification to add safety ocular x-ray to study; PVAMC IRB approval 3/29/2013.
• Modification to add safety ocular x-ray to study; OHSU IRB approval 4/28/2013.
• Dr. Fergus Coakley, OHSU Diagnostic Radiology Chair agrees to collaborate, consult and share his MRI in prostate cancer expertise with the investigational team, 5/20/2013.
• Modification to exclude recently-prescribed statin users (i.e.: on statin drug for less than 6 months) from study, increase to number of men (to 140); PVAMC IRB approval 6/18/2013.
• As of August 29, 2013, 9 men consented to study; 1 pending MRSI, 6 successful MRSIs, 2 screen fails. Figure 1a shows a T 2 *-weighted axial image of a subject's pelvis area. A prostate lesion is indicated in red. Panel 1b shows a zoomed lipid color map with the lipid content normalized to maximum total water and fat signal. Elevated lipid content is visible in the lesion area (red dished circle). It is worth noting that periprostatic lipid content is generally high (2). This is obvious with noticeable hot spots around the prostate even when multi-band lipid saturation is prescribed.
